Michael Lind

4.9k total citations
118 papers, 3.6k citations indexed

About

Michael Lind is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Molecular Biology. According to data from OpenAlex, Michael Lind has authored 118 papers receiving a total of 3.6k indexed citations (citations by other indexed papers that have themselves been cited), including 53 papers in Oncology, 40 papers in Pulmonary and Respiratory Medicine and 33 papers in Molecular Biology. Recurrent topics in Michael Lind's work include Lung Cancer Treatments and Mutations (20 papers), Lung Cancer Research Studies (16 papers) and Chemotherapy-induced organ toxicity mitigation (14 papers). Michael Lind is often cited by papers focused on Lung Cancer Treatments and Mutations (20 papers), Lung Cancer Research Studies (16 papers) and Chemotherapy-induced organ toxicity mitigation (14 papers). Michael Lind collaborates with scholars based in United Kingdom, United States and Australia. Michael Lind's co-authors include Lynn Cawkwell, Philip Drew, Lawrence K. Duffy, Hideyo Inouye, Laura Smith, Daniel A. Kirschner, Dennis J. Selkoe, Alison J. Sinclair, Mark B. Watson and Sara L. O’Kane and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Journal of Clinical Oncology and SHILAP Revista de lepidopterología.

In The Last Decade

Michael Lind

113 papers receiving 3.5k citations

Peers

Countries citing papers authored by Michael Lind

Since Specialization

Citations

This map shows the geographic impact of Michael Lind's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Michael Lind with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Michael Lind more than expected).

Fields of papers citing papers by Michael Lind

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Michael Lind. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Michael Lind. The network helps show where Michael Lind may publish in the future.

Co-authorship network of co-authors of Michael Lind

This figure shows the co-authorship network connecting the top 25 collaborators of Michael Lind. A scholar is included among the top collaborators of Michael Lind based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Michael Lind. Michael Lind is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Geriatric Oncology as an Unmet Workforce Training Need in the United Kingdom—A Narrative Review by the British Oncology Network for Undergraduate Societies (BONUS) and the International Society of Geriatric Oncology (SIOG) UK Country Group 2023 ·Cancers ·(unknown), (unknown), (unknown), (unknown), (unknown), (unknown), Tania Kalsi, Fábio Gomes, Michael Lind, Nicolò Matteo Luca Battisti, Kwok‐Leung Cheung, Ruth Parks, (unknown), Mark Baxter	4
2	Where are the inequalities in ovarian cancer care in a country with universal healthcare? A systematic review and narrative synthesis 2023 ·Journal of Cancer Policy ·Benjamin Pickwell‐Smith, Sarah Greenley, Michael Lind, Una Macleod	7
3	Geographical distance and reduced access to palliative radiotherapy: systematic review and meta-analysis 2022 ·BMJ Supportive & Palliative Care ·(unknown), Sarah Greenley, Una Macleod, Michael Lind, (unknown), Charlotte Kelly	6
4	PUB068 The Applicability of Comorbidity Indices in Predicting Chemo toxicity in Non-Small Cell Lung Cancer 2017 ·Journal of Thoracic Oncology ·(unknown), Michael Lind, (unknown), Reza Mafi, Karen Wallace, Gareth R. Howell, (unknown), (unknown)	1
5	Effect of Comorbidity on Surgery and Survival Among Lung Cancer Patients in England 2015 ·Annals of Oncology ·Margreet Lüchtenborg, (unknown), Ruth H. Jack, Michael Peake, Michael Lind, Henrik Møller	1
6	High Procedure Volume Is Strongly Associated With Improved Survival After Lung Cancer Surgery 2013 ·Journal of Clinical Oncology ·Margreet Lüchtenborg, Sharma P. Riaz, Victoria H. Coupland, Eric Lim, Erik Jakobsen, Mark Krasnik, Richard Page, Michael Lind, Michael Peake, Henrik Møller	153
7	Pilot and feasibility study: comparative proteomic analysis by 2-DE MALDI TOF/TOF MS reveals 14-3-3 proteins as putative biomarkers of response to neoadjuvant chemotherapy in ER-positive breast cancer 2012 ·Journal of Proteomics ·(unknown), (unknown), Dalia Elfadl, John Fox, Penelope McManus, Tapan Mahapatra, Peter Kneeshaw, Philip Drew, Michael Lind, Lynn Cawkwell	33
8	Repeatedly identified differentially expressed proteins (RIDEPs) from antibody microarray proteomic analysis 2011 ·Journal of Proteomics ·(unknown), Dalia Elfadl, Philip Drew, Michael Lind, Lynn Cawkwell	11
9	Biomarkers of chemotherapy resistance in breast cancer identified by proteomics: Current status 2010 ·Cancer Letters ·(unknown), Gina Eagle, Philip Drew, Michael Lind, Lynn Cawkwell	30
10	Appropriate requesting of serum tumour markers 2009 ·BMJ ·Eric S Kilpatrick, Michael Lind	23
11	Intravenous administration of CP-4055 (ELACYT™) in patients with solid tumours. A phase I study 2008 ·Acta Oncologica ·Svein Dueland, Steinar Aamdal, Michael Lind, Hilary Thomas, Marit Liland Sandvold, (unknown), Wenche Rasch	27
12	Pharmacokinetics of a nucleoside analogue CP-4055 in two phase I trials using a daily for 5 days schedule and three intermittent weekly or biweekly schedules 2005 ·Cancer Research ·Éric Raymond, Svein Dueland, Michael Lind, Ahmad Awada, Hilary Thomas, Stéphane Culine, Alejandro Yovine, William Sutherland, (unknown), Wenche Rasch	2
13	Karyotypic variation between independently cultured strains of the cell line MCF-7 identified by multicolour fluorescence in situ hybridization 2002 ·International Journal of Oncology ·(unknown), (unknown), Lynn Cawkwell, Michael Lind, John R.T. Monson, Phil Drew, John Greenman	38
14	Ifosfamide metabolism and DNA damage in tumour and peripheral blood lymphocytes of breast cancer patients 2000 ·Cancer Chemotherapy and Pharmacology ·Elaine Johnstone, Michael Lind, Martin J. Griffin, Alan V. Boddy	21
15	Pharmacokinetics, metabolism and clinical effect of ifosfamide in breast cancer patients 1995 ·European Journal of Cancer ·Alan V. Boddy, (unknown), (unknown), Michael Lind, Jeffrey R. Idle	36
16	Identification of the major human hepatic cytochrome P450 involved in activation and N-dechloroethylation of ifosfamide 1994 ·Biochemical Pharmacology ·Dianne Walker, Jean-Pierre Flinois, (unknown), (unknown), Alan V. Boddy, S. Cholerton, Ann K. Daly, Michael Lind, (unknown), Philippe Beaune, Jeffrey R. Idle	105
17	Long-term oral etoposide in metastatic breast cancer: clinical and pharmacokinetic results 1993 ·Cancer Treatment Reviews ·A H Calvert, Michael Lind, (unknown), B.M.J. Cantwell, Lindsey Gumbrell, (unknown), (unknown), (unknown), Andrew Robinson, (unknown), Kathryn Balmanno, David R. Newell	30
18	Prevalence of the rhesus‐negative phenotype in caucasian patients with small‐cell lung cancer (SCLC) 1992 ·International Journal of Cancer ·T. Cerny, Martin F. Fey, Rolf Oppliger, M. Castiglione, B Nachbur, (unknown), Andreas Gasser, R Joss, N. Thatcher, Michael Lind, A. von Rohr, Urs E. Nydegger	18
19	High-dose, double alkylating agent chemotherapy with DTIC, melphalan, or ifosfamide and marrow rescue for metastatic malignant melanoma 1989 ·Cancer ·Nick Thatcher, Michael Lind, G.R. Morgenstern, (unknown), (unknown), Robert H. Jones, Peter Craig	21
20	Cyclosporin associated demyelination following allogeneic bone marrow transplantation 1989 ·Hematological Oncology ·Michael Lind, L J McWilliam, (unknown), J.H. Scarffe, G.R. Morgenstern, James Chang	9

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact